Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

ATTO Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Attovia Therapeutics, Inc.NASDAQ: ATTO

Retained Earnings · Q2 FY2026 · quarter ended Jun 2026

Retained earnings of -$150.35M in Q2 FY2026

Q2 FY2026 retained earnings was -$150.35M.

Context

  • Retained earnings amounted to 117.1% of total assets at the end of Q2 FY2026.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$150.35M-16.0% QoQ
Last fiscal yearDec 2025
-$111.01M-120.3% YoY
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-120.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(111.01M) USD
Year-over-year change
-120.3%

Retained Earnings vs competitors

How ATTO compares with its peers on the latest reported figures

  • Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
  • Retained earnings amounts to 117.1% of total assets for ATTO, versus a peer median of 167.9%.
ATTO Competitors
Retained Earnings for ATTO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ATTOAttovia Therapeutics, Inc.Jun 2026-$150.35M USD——117.1%
AGMBAgomAb Therapeutics N.V. American Depositary SharesSep 2025-€164.27M EUR——99.2%
QTTBQ32 Bio Inc.Mar 2026-$212.6M USD+13.5%—333.9%
EVMNEvommune, Inc.Mar 2026-$242.76M USD-45.6%—75.3%
ZURAZura Bio LimitedMar 2026-$248.77M USD-43.5%—108.8%
ORKAOruka Therapeutics, Inc.Sep 2026-$312.15M USD-95.6%—25.4%
CNTBConnect Biopharma Holdings LimitedDec 2025-$400.84M USD-16.1%—714.8%
MLTXMoonLake ImmunotherapeuticsMar 2026-$532.62M USD-93.3%—133.0%
ANABAnaptysBio, Inc.Mar 2026-$825.44M USD-3.4%—250.4%
ACRSAclaris Therapeutics, Inc.Mar 2026-$987.61M USD-7.6%—497.0%
ALMSAlumis Inc. Common StockJun 2026-$1.14B USD-62.9%—202.8%
Peer median (excluding ATTO) —-43.5%—167.9%

Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Attovia Therapeutics, Inc.

NASDAQ:ATTO

Intrinsic Alpha fair value

Locked

Current Price

$15.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.